SCHEMBL670980

SCHEMBL670980

Cc1ccccc1C#CC(=O)O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 10/20 0.49
FFAR4 Q5NUL3 2/20 0.49
CHRM2 P08172 1/20 0.49
S1PR1 P21453 1/20 0.49
FPR1 P21462 1/20 0.49
FPR3 P25089 1/20 0.49
GPR183 P32249 1/20 0.49
APLNR P35414 1/20 0.49
GPR65 Q8IYL9 1/20 0.49
TSHR P16473 1/20 0.45
GRM5 P41594 1/20 0.43
HSP90AA1 P07900 1/20 0.42
NTSR1 P30989 1/20 0.42
IKBKB O14920 1/20 0.39
ERCC5 P28715 1/20 0.39
FEN1 P39748 1/20 0.39
VCP P55072 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
AR P10275 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30231559 1.00 FFAR1 (0.49) FFAR1FFAR4CHRM2S1PR1FPR1
SCHEMBL30772315 0.84 HSP90AA1 (0.48) FFAR1TSHRHSP90AA1NTSR1VCP
SCHEMBL12430910 0.83 FFAR1 (0.45) FFAR1FFAR4CHRM2S1PR1FPR1
SCHEMBL27167218 0.82 HSP90AA1 (0.64) FFAR1FFAR4CHRM2S1PR1FPR1
SCHEMBL11572436 0.82 IKBKB (0.44) FFAR1FFAR4CHRM2S1PR1FPR1
SCHEMBL6563215 0.79 FFAR1 (0.42) FFAR1FFAR4CHRM2S1PR1FPR1
SCHEMBL15841077 0.79 FFAR1 (0.45) FFAR1FFAR4CHRM2S1PR1FPR1
SCHEMBL6329854 0.77 FFAR1 (0.44) FFAR1FFAR4CHRM2S1PR1FPR1
SCHEMBL17407733 0.77 CYP1A2 (0.46) FFAR1FFAR4CHRM2S1PR1FPR1
SCHEMBL25229437 0.77 FFAR1 (0.47) FFAR1ERCC5FEN1VCPNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822628-B2 Crosslinkable liquid crystalline polymer TICONA LLC (US) 2014-09-02 US claimed
US-20140088285-A1 Crosslinkable Liquid Crystalline Polymer TICONA LLC (US) 2014-03-27 US claimed
CN-1183133-C 2-amino-6-anilino-purines and their use as medicaments ��˹��ŵ�� 2005-01-05 CN claimed
CN-1340054-A 2-amino-6-anilino-purines and their use as medicaments NOVARTIS AG (CH) 2002-03-13 CN claimed
WO-2023114539-A1 AMINO CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-06-22 WO disclosed
CN-110498773-B Method for synthesizing 1, 4-substituted 1,2, 3-triazole from acetylenic acid 乐山师范学院 2021-07-02 CN disclosed
CN-107556269-B Synthetic method of alpha-alkynyl substituted ether compound 南京理工大学 2020-11-06 CN disclosed
US-20170267824-A1 PREPREG COMPOSITE CONTAINING A CROSSLINKED AROMATIC POLYESTER TICONA LLC 2017-09-21 US disclosed
EP-2606025-B1 PROCESS FOR PREPARING A PROPIOLIC ACID OR A DERIVATIVE THEREOF BASF SE (DE) 2016-10-12 EP disclosed
US-20150274886-A1 Crosslinkable Soluble Aromatic Polyester TICONA LLC 2015-10-01 US disclosed
US-9145519-B2 Crosslinkable aromatic polyester TICONA LLC (US) 2015-09-29 US disclosed
US-9073844-B2 Process for preparing a propiolic acid or a derivative thereof BASF SE (DE) 2015-07-07 US disclosed
EP-1224189-B1 CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 LILLY CO ELI (US) 2006-01-25 EP disclosed
CN-1183133-C 2-amino-6-anilino-purines and their use as medicaments ��˹��ŵ�� 2005-01-05 CN disclosed
US-20040077675-A1 Compounds and methods for inhibiting MRP1 BONJOUKLIAN ROSANNE (US) 2004-04-22 US disclosed
US-6670373-B1 Inhibiting resistant neoplasms where the resistance is conferred by multidrug resistance protein; N-3,4,5-trimethoxyphenyl-3-(3-azidomethyl-isoxazolo(4,5-c) -1,2-dihydro-6-chloro-quinolin-2-on-1-yl)phenylacetamide ELI LILLY AND COMPANY 2003-12-30 US disclosed
EP-1224189-A2 CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2002-07-24 EP disclosed
CN-1340054-A 2-amino-6-anilino-purines and their use as medicaments NOVARTIS AG (CH) 2002-03-13 CN disclosed
WO-2001027116-A2 CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2001-04-19 WO disclosed
US-4647526-A Heat-developable light-sensitive material FUJI PHOTO FILM CO., LTD. (JP) 1987-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077675-A1 Compounds and methods for inhibiting MRP1 ABCC1, ABCB1, ABCB11 FFAR1 4492/4885FFAR4 4848/4885CHRM2 4808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.